LightDeck Diagnostics has selected GS Plastic Optics to manufacture optical components for its new COVID-19 antibody test platform.
LightDeck, based in Boulder, Colorado, has developed a screening platform to deliver results for SARS-CoV-2 ultra-rapid antigen and COVID-19 total antibody tests in just five minutes using a laser waveguide with a consumable cartridge for each test sample is used.
GS Plastic Optics (GSPO), based in Rochester, New York, will be the primary source for this sophisticated laser waveguide, which will require a $ 5 million expansion in Rochester for an 8,000-square-foot injection molding facility expansion and additional presses and tools and ancillary equipment .
The funds for the GSPO expansion come from one Federal contract for $ 35 million to expand LightDeck’s monthly test production capacity from 50,000 to 1 million by fall 2022.
“During the several years that we have worked with GSPO, we have built a trusting, partnership-based relationship with their development and production teams,” said Nick Traggis, CEO of LightDeck, in a Press release. “Your impeccable attention to detail fits in very well with our own product strategy and you are available as a powerful domestic partner to support the scope of our testing capacities.”
“Today more than ever, our goal is to support the medical community in their great strides to improve the health care of our nation,” said GSPO CEO Andy Germanow in the press release. “Especially during this pandemic, point-of-care tests are in the foreground for us, and we strive to deliver precision components that are built to specification.”